Program by Day

« Back

Print this page

	Personalized Program The Personalized Program enables you to compile an individual program with events and contributions of your interest. Therefore, it can be used very well to plan your actual congress visit at an early point of time. Please log in to use the Personalized Program.	» Login » Identification » Help

« previous day	Tuesday, 30. June 2009	next day »

No.	S-43 - Symposium
Time:	08.00-09.30
Room:	Blue Amphitheatre
Topic:	Brain Function
Track:	3 Interface
Session title:	Immune activation and tryptophan metabolism in major psychiatric disorders
	Markus J. Schwarz, Germany	Chair
	Gilles Guillemin, Australia	Co-Chair

001	Tryptophan metabolism by astrocytes and microglia in neurodegenerative diseases
	Gilles Guillemin, Australia	Speaker
002	The outcome of postmortem studies of schizophrenia and bipolar disorder: Genes of relevance to tryptophan metabolism
	Christine L. Miller, USA	Speaker
003	Immune and tryptophan catabolic markers in blood and cerebrospinal fluid of patients with major depression and schizophrenia
	Aye-Mu Myint, Germany	Speaker
004	Immunomodulating therapy in major depression and schizophrenia
	Norbert Müller, Germany	Speaker

No.	S-44 - Symposium
Time:	08.00-09.30
Room:	Salle Maillot
Topic:	Affective Disorders (Bipolar)
Track:	3 Interface
Session title:	60 years of lithium in neuropsychiatry - recent discoveries in basic and clinical research
	Michael Bauer, Germany	Chair
	Janusz Rybakowski, Poland	Co-Chair

001	Response to long-term lithium treatment and its use as an endophenotype for bipolar disorder
	Martin Alda, Canada	Speaker
002	Neuroprotective properties of lithium
	Robert Belmaker, Israel	Speaker
003	Genome-wide findings from the Consortium on Lithium Genetics (ConLiGen)
	Thomas G. Schulze, USA	Speaker
004	Lithium at work: The neurobiologist's perspective -from animal models to the development of novel therapeutics
	Husseini Manji, USA	Speaker

No.	S-45 - Symposium
Time:	08.00-09.30
Room:	Room 352AB
Topic:	Psychopharmacology
Track:	3 Interface
Session title:	Are biological measures useful in predicting antipsychotic treatment response in schizophrenia?
	Monte Buchsbaum, USA	Chair
	Herbert Meltzer, USA	Co-Chair

001	Prediction of antipsychotic response with diffusion tensor imaging
	M. Mehmet Haznedar, USA	Speaker
002	Pharmacogenetic prediction of antipsychotic response
	Maria Arranz, United Kingdom	Speaker
003	Predicting best treatment response in schizophrenia with striatal function
	Erin Hazlett, USA	Speaker
004	Loudness dependence of auditory evoked potentials as predictor of therapeutical response to psychotropic medication
	Georg Juckel, Germany	Speaker

No.	S-46 - Symposium
Time:	08.00-09.30
Room:	Room 252B
Topic:	Addictive Disorders
Track:	1 Basic
Session title:	Dysregulation of neurogenesis in the brain action: The common mechanism of alcoholism and depression
	Toshikazu Saito, Japan	Chair
	Stefan Brene, Sweden	Co-Chair

001	Stem cells and alcohol dependence: Suppressed neurogenesis after long periods of abstinence
	Anita C. Hansson, Germany	Speaker
002	Depending on dose and context, alcohol consumption can both increase and decrease hippocampal neurogenesis in rodents
	Stefan Brene, Sweden	Speaker
003	Effects of chronic ethanol exposure on long-term differentiation of SH-SY5Y human neuroblastoma cells
	Julian D. Hellmann, Germany	Speaker
004	Potential regulation of neurogenesis by psychotropics in the damaged brain by ethanol
	Eri Hashimoto, Japan	Speaker

No.	S-47 - Symposium
Time:	08.00-09.30
Room:	Room 241
Topic:	Genetics
Track:	3 Interface
Session title:	Biological markers and clinical features in depression: A difficult puzzle
	Eduardo Rubio Dominguez, Argentina	Chair
	Florence Thibaut, France	Co-Chair

001	The relevant relationship between genetic and clinical presentation
	Raquel Teresa Zamora-Cabral, Uruguay	Speaker
002	Neuropsycological endophenotypes in bipolar disorder
	Carlos Lopez Jaramillo, Colombia	Speaker
003	International studies on SERT and subtypes of depression - an update
	Andrea Lopez Mato, Argentina	Speaker
004	Correlation between the Serotonin transporter gene in depressive patients and suicide victims
	Patricia Chieri, Argentina	Speaker

No.	S-48 - Symposium
Time:	08.00-09.30
Room:	Room 251
Topic:	Psychotic Disorders
Track:	1 Basic
Session title:	New findings on the neurobiological basis of language abnormalities in schizophrenia
	Werner Strik, Switzerland	Chair
	Robert McCarley, USA	Co-Chair

001	Contribution of gene-brain interaction to language abnormalities in schizophrenia
	Tilo Kircher, Germany	Speaker
002	Disordered thought and impaired connectivity of language regions in schizophrenia
	Robert McCarley, USA	Speaker
003	Abnormalities of the language circuitry in schizophrenic thought disorders and hallucinations
	Werner Strik, Switzerland	Speaker
004	Language deficits in schizophrenia: Evidence from behavioral, functional and connectivity studies
	Ruben Gur, USA	Speaker

No.	FC-15 - Free Communications
Time:	08.00-09.30
Room:	Room 351
Topic:	Affective Disorders (Unipolar)
Session title:	Affective Disorders (Unipolar) II
	Ulrich-Michael Hemmeter, Switzerland	Chair
	Edith Holsboer-Trachsler, Switzerland	Co-Chair

001	Inter-individual differences in positive affect and vulnerability to chronic stress in the rat: A model for male depression?
	Jaanus Harro, Estonia	Speaker
002	Depression is associated with decreased blood pressure but antidepressant use increases the risk for hypertension
	Carmilla Licht, Netherlands	Speaker
003	Association between lifetime hormonal factors and hormone therapy, with late-life depression in women
	Marie Laure Ancelin, France	Speaker
004	Anti-stress and anti-oxidative effects of St. John´s wort extract (STW 3-VI) in a model of chronic stress
	Olaf Kelber, Germany	Speaker
005	Depersonalization and depressive phenomenology in unipolar depression
	Olivera Zikic, Serbia and Montenegro	Speaker
006	HPA-axis activity in a large cohort of depressed and anxious subjects
	Sophie Vreeburg, Netherlands	Speaker

No.	FC-16 - Free Communications
Time:	08.00-09.30
Room:	Room 242A
Topic:	Neuroimaging
Session title:	Neuroimaging I
	Eric Hollander, USA	Chair
	Lars Farde, Sweden	Co-Chair

001	The neural correlates of grief due to unrequited love
	Christina Stoessel, Germany	Speaker
002	Investigation of orbitofrontal sulcogyral pattern: Is it possible to distinguish individuals with schizophrenia from those with bipolar disorder?
	Goultchira Chakirova, United Kingdom	Speaker
003	Reproducibility of functional Magnetic Resonance Imaging activations in schizophrenic patients during story comprehension: Impact of task performance
	Olivier Maïza, France	Speaker
004	Emotional modulation of working memory and the influence of the COMT polymorphism
	Sylvia Richter, Germany	Speaker
005	Prefrontal transcranial Direct Current Stimulation (tDCS) modulates resting-state functional connectivity in healthy subjects: A functional magnetic resonance imaging (fMRI) study
	Julie Bor, France	Speaker
006	Structural brain differences between first-episode schizophrenia and first-episode affective psychosis: A population-based magnetic resonance imaging study
	Pedro Rosa, Brazil	Speaker

No.	FC-17 - Free Communications
Time:	08.00-09.30
Room:	Room 242B
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders V
	Rainald Mössner, Germany	Chair
	Michael Musalek, Austria	Chair

001	A functional MRI study of face perception in patients with schizophrenia
	Yasuhiro Kawasaki, Japan	Speaker
002	Arousal-cognition decoupling in Schizophrenia: An EEG-fMRI study
	Jack Foucher, France	Speaker
003	Global abnormalities in white and gray matter of chronic schizophrenia: A diffusion tensor imaging study
	Motoaki Nakamura, Japan	Speaker
004	Detection of 6p25 region in male schizophrenia via fluorescence in SITU hybridization (FISH) techniques
	Pappuswamy Manikantan, India	Speaker
005	Metabolic derangement in schizophrenia: Relation to antipsychotic treatment
	Marwa Soltan, Egypt	Speaker
006	Influence of antypsychotic treatment on cognitive functions in schizophrenia with comorbid addiction to substances
	Krzysztof Krysta, Poland	Speaker

No.	PL-03 - Plenary Lecture
Time:	09.45-10.30
Room:	Main Amphitheatre
Topic:	Addictive Disorders
Session title:	Addiction and the neurobiology of choice and self-control
	Siegfried Kasper, Austria	Chair

001	Addiction and the neurobiology of choice and self-control
	Nora Volkow, USA	Speaker

No.	YS-03 - Young Scientists Award Session
Time:	09.45-10.30
Room:	Room 242A
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders I
	Michel Dierick, Belgium	Chair
	Gerhard Gründer, Germany	Co-Chair

001	Plasmatic Glutathione levels and their relationships with clinical and therapeutic features in schizophrenic patients
	Monia Raffa, Tunisia	Speaker
002	What can the N170 tell us about face processing in schizotypy?
	Rachel Batty, Australia	Speaker
003	Identification of novel Clozapine interactions with the Phosphatidyl Inositol 3-Kinase (PI3K)/Insulin signaling pathway in a Caenorhabditis elegans model system
	Rakesh Karmacharya, USA	Speaker

No.	TG-05 - WFSBP Treatment Guidelines
Time:	11.00-12.30
Room:	Room 242A
Topic:	Affective Disorders (Bipolar)
Session title:	Bipolar disorders
	Guy Goodwin, United Kingdom	Chair

	Eduard Vieta, Spain	Presenter
	Heinz Grunze, United Kingdom	Presenter

No.	SL-02 - Special Lecture
Time:	11.00-12.00
Room:	Blue Amphitheatre
Topic:	Brain Function
Session title:	From tragedy to tears: A neurobiological perpective
	René Kahn, Netherlands	Chair

001	From tragedy to tears: A neurobiological perspective
	Michael Trimble, United Kingdom	Speaker

No.	D-05 - Debate
Time:	11.00-12.30
Room:	Room 351
Topic:	Psychopharmacology
Session title:	Are psychotropic drugs overprescribed to pregnant women ?
	Birte Glenthoj, Denmark	Chair

	Angelika Wieck, United Kingdom	Proponent
	Pierre Thomas, France	Opponent

No.	W-07 - Workshop
Time:	11.00-12.30
Room:	Room 242B
Topic:	Other
Session title:	Exploring mental disorders in evolutionary perspective
	Martin Brüne, Germany	Chair

001	Is clinical neuroscience's brain evolutionarily informed?
	Horacio Fabrega, USA	Speaker
002	Darwinian psychiatry as an antidote against medicalization of human diversity
	Alfonso Troisi, Italy	Speaker
003	Gene-environment interaction in psychiatry: An evolutionary approach
	Julio Sanjuan, Spain	Speaker
004	Exploring social brain dysfunction in evolutionary perspective
	Martin Brüne, Germany	Speaker

No.	S-49 - Symposium
Time:	11.00-12.30
Room:	Salle Maillot
Topic:	Brain Function
Track:	2 Clinical
Session title:	Translational medicine in psychiatry; making sense of preclinical and clinical research: Methodologies, opportunities, and controversies
	Husseini Manji, USA	Chair
	Andrea De Bartolomeis, Italy	Co-Chair

001	Translational medicine of bipolar disorders
	Husseini Manji, USA	Speaker
002	Genetically determined dopamine signaling in schizophrenia phenotypes
	Alessandro Bertolino, Italy	Speaker
003	Major depressive disorder is a risk factor for osteoporosis in women
	Cizza Giovanni, USA	Speaker
004	Traslational studies and the search for new targets in psychosis treatment, methodology, success and failure
	Andrea De Bartolomeis, Italy	Speaker

No.	S-50 - Symposium
Time:	11.00-12.30
Room:	Room 352AB
Topic:	Psychotic Disorders
Track:	1 Basic
Session title:	Microglia in psychiatric disorders
	Natalia Uranova, Russia	Chair
	Norbert Müller, Germany	Co-Chair

001	Microglia as an immune source: The possible role in schizophrenia and depression
	Norbert Müller, Germany	Speaker
002	Glial Cell Changes and Gene expression in the Brain and Blood in Schizophrenia
	Ian Everall, USA	Speaker
003	The distribution of microglia in post-mortem brains of patients with schizophrenia and depression
	Johann Steiner, Germany	Speaker
004	Ultrastructural abnormalities of microglial cells in post-mortem brains in schizophrenia
	Natalia Uranova, Russia	Speaker

No.	S-51 - Symposium
Time:	11.00-12.30
Room:	Room 252B
Topic:	Addictive Disorders
Track:	2 Clinical
Session title:	Cannabis: What's happening?
	Amine Benyamina, France	Chair
	Michel Reynaud, France	Co-Chair

001	Pharmacological treatment of cannabis dependence
	Margaret Haney, USA	Speaker
002	Cannabis and psychiatric co-morbidity
	Stanley Zammit, United Kingdom	Speaker
003	Cannabis: Legal aspects and decriminalisation
	Wim van den Brink, Netherlands	Speaker
004	Pharmacogenetic vulnerability
	Amine Benyamina, France	Speaker

No.	S-52 - Symposium
Time:	11.00-12.30
Room:	Room 241
Topic:	Neurodegenerative Disorders
Track:	3 Interface
Session title:	Clinical and biological aspect of apathy in neuropsychiatry
	Philippe Robert, France	Chair
	Albert Leentjens, Netherlands	Co-Chair

001	The concept of apathy in Alzheimer's disease
	Albert Leentjens, Netherlands	Speaker
002	Apathy in other neurodegenerative diseases
	Kathy Dujardin, France	Speaker
003	Ambulatory actigraphy for the evaluation of apathy in Alzheimer's disease
	Renaud David, France	Speaker
004	Discussion
	Philippe Robert, France	Speaker

No.	S-53 - Symposium
Time:	11.00-12.30
Room:	Room 251
Topic:	Anxiety
Track:	1 Basic
Session title:	Neurobiological correlates of dissociation and influence on information processing in stress-related disorders
	Eric Vermetten, Netherlands	Chair
	Petra Ludäscher, Germany	Co-Chair

001	Neural correlates of dissociation in patients with posttraumatic stress disorder
	Eric Vermetten, Netherlands	Speaker
002	The neural correlates of emotional distraction during working memory performance in traumatized patients with borderline personality disorder
	Annegret Krause, Germany	Speaker
003	Influence of dissociation on information processing in stress-related disorders
	Jana Mauchnik, Germany	Speaker
004	Neural correlates of dissociation in patients with borderline personality disorder
	Ruth Lanius, Canada	Speaker

No.	FC-18 - Free Communications
Time:	12.30-14.00
Room:	Room 351
Topic:	Anxiety
Session title:	Anxiety II
	Veronica Larach-Walters, Chile	Chair
	Martijn Figee, Netherlands	Co-Chair

001	Transgenerational transmission of trauma - case of Albania
	Ariel Como, Albania	Speaker
002	Reduced resting state connectivity between amygdala and orbitofrontal cortex in social phobia
	Patrycja Stein, Austria	Speaker
003	Examining changes in resistant anxiety symptoms of ADHD with co-morbid generalized anxiety disorder in adult patients treated with mixed amphetamine salts (adderall XR)
	Adel Gabriel, Canada	Speaker
004	GSK3ß as a biological marker of stress in the prefrontal cortex
	Julie Bourgin, France	Speaker
005	Personality and clinical correlates of response to a laboratory stressor in patients with social anxiety disorder
	Diana Koszycki, Canada	Speaker
006	Long term consequences on mental health of traumatic exposure in an elderly general population and impact of genetic vulnerability
	Isabelle Chaudieu, France	Speaker

No.	FC-19 - Free Communications
Time:	12.30-14.00
Room:	Room 242A
Topic:	Psychopharmacology
Session title:	Psychopharmacology II
	Christer Allgulander, Sweden	Chair
	Herbert Meltzer, USA	Co-Chair

001	Characteristic of clozapine responders & non-responders in a naturalistic tertiary setting in India
	Amresh Shrivastava, Canada	Speaker
002	Effects of Olanzapine and Risperidone on glucose metabolism and Insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: A randomized five month study
	Robert C. Smith, USA	Speaker
003	Antipsychotic polypharmacy and use of sedatives and hypnotics in outpatients at Birch Hill Hospital - incidence and adherence to guidelines
	Nadezda Ranceva, United Kingdom	Speaker
004	Patterns of Risperidone long acting prescription: A utilization study in Saudi Arabia
	Khalaf Aljumaah, Saudi Arabia	Speaker
005	Antioxidant neuroprotection by neuroleptics revisited
	Parvana Hajieva, Germany	Speaker
006	Fitness to drive under escitalopram or mirtazapine
	Gerd Laux, Germany	Speaker

No.	FC-20 - Free Communications
Time:	12.30-14.00
Room:	Room 242B
Topic:	Genetics
Session title:	Genetics II
	Michel Hamon, France	Chair
	Olya Mikova, Bulgaria	Co-Chair

001	Moderate caloric restriction reduces anxiety-like behavior and changes gene expression in the mouse amygdala
	Yuta Yamamoto, Japan	Speaker
002	Impact of schizophrenia candidate genes on smooth eye pursuit in a population of young men
	Nikolaos Smyrnis, Greece	Speaker
003	Catechol-O-Methyltransferase (COMT) gene and response to cognitive remediation in schizophrenia: Preliminary findings
	Jean-Pierre Lindenmayer, USA	Speaker
004	Association between dopaminergic pathway gene polymorphisms and schizophrenia (SCHZ) in Malaysian individuals
	Pek Yee Tang, Malaysia	Speaker
005	Conditional CRH overexpressing mouse mutants: Dissecting CRH-sensitive pathways in vivo
	Jan Deussing, Germany	Speaker
006	GAB2, GSTP1, SORL1, BDNF, GAPDH and APOE, polymorphisms associated with late onset Alzheimer disease
	Elida Ojopi, Brazil	Speaker

No.	P-22 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Affective Disorders (Bipolar)
Session title:	Affective Disorders (Bipolar/Unipolar)
	Jose Luis Ayuso Gutierrez, Spain	Chair

001	Social perception and emotion regulation in bipolar disorder and schizophrenia
	Melissa Green, Australia	Presenter
002	The prevalence of metabolic syndrome in Tunisian patients with bipolar I disorder
	Asma Ezzaher, Tunisia	Presenter
003	Vagus nerve stimulation in treatment-resistant depression: An Italian case-series
	Bernardo Dell’Osso, Italy	Presenter
004	Gender differences in relation to comorbidity patterns and abuse in bipolar disorder
	Bernardo Dell’Osso, Italy	Presenter
005	Eating disorder and bipolar disorder: A hard to treat comorbidity
	Diogo Guerreiro, Portugal	Presenter
006	Risk of cancer and HIV infection in patients with bipolar disorder: A systematic review
	Julio Bobes, Spain	Presenter
007	Treatment with escitalopram of patients with depressive disorders admitted in a general hospital
	Jose Luis Rodriguez, Spain	Presenter
008	Prevalence of mixed episode in Korean bipolar patients
	Kyung-Joon Min, Korea, Republic of	Presenter
009	Neural oscillatory activity to speech sounds in bipolar disorder
	Naoya Oribe, Japan	Presenter
010	Affective disorders as risk factors for delirium after cardiac surgery
	Phillip J. Tully, Australia	Presenter
011	Columbia University Lithium Archives Project: Bridging the gap from laboratory evidence to clinical findings
	Ronald Fieve, USA	Presenter
012	Bipolar Disorders (BPD) in Emergency Departments (ED) in Latin-America: Prevalence and associated comorbidity
	Ruby Castilla-Puentes, USA	Presenter
013	Chronic musculoskeletal pain: Depression, anxiety and altered cytokine levels
	Saskia Hahnenkamp, Germany	Presenter
014	Effect of Melatonin on the serotonergic neural activity across the light-dark cycle
	Sergio Dominguez Lopez, Canada	Presenter
015	Lithium effects on the chronobiological model of affective disorder
	Tatyana Zamoshchina, Russia	Presenter
016	The Redundant Signal Effect as index of abnormal interhemispheric integration in schizophrenic and bipolar patients
	Vincenzo Florio, Italy	Presenter
017	Auditory sensory gating deficit to voices in patients with psychotic bipolar disorder: A MEG study
	Yoji Hirano, Japan	Presenter
018	Depression and coagulation of blood
	Elena Mikhaylova, Russia	Presenter
019	Headache and personal disorders in local wars participants
	Elena Mikhaylova, Russia	Presenter

No.	P-23 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Anxiety
Session title:	Anxiety II
	Gerardo M. Heinze, Mexico	Chair

001	Is there a Metabolic Syndrome in PTSD: Lipid level alterations in veterans with chronic PTSD
	Alma Dzubur Kulenovic, Bosnia and Herzegovina	Presenter
002	Safety and efficacy of Venlafaxine in the treatment of depressive disorder comorbid with generalized anxiety disorder
	Alma Dzubur Kulenovic, Bosnia and Herzegovina	Presenter
003	A controlled trial of Eye Movement Desensitisation and Reprocessing (EMDR) treatment for phobia
	Antoine Pelissolo, France	Presenter
004	Initial CAPS measurement after psychic trauma strongly correlates with changes of hippocampal volume after one and after six months
	Dino Santangelo de Souza, Germany	Presenter
005	Lymphocyte glucocorticoid receptor expression and functional properties in Balkan war veterans with and without PTSD
	Gordana Matic, Serbia and Montenegro	Presenter
006	Pharmacotherapy of the complex Posttraumatic Stress Disorder
	Grozdanko Grbesa, Serbia and Montenegro	Presenter
008	Glucocorticoid receptor mRNA level in war veterans with and without PTSD
	Jelena Brkljacic, Serbia and Montenegro	Presenter
009	Complement system as a key component of immune respone associated with posttraumatic stress disorder
	Lilit Hovhannisyan, Armenia	Presenter
010	A quality of life in chronic combat related Posttraumatic Stress Disorder (PTSD): A study on Croatian war veterans
	Marijana Bras, Croatia	Presenter
011	The connection between coping mechanisms, depression, anxiety and fatigue in multiple sclerosis
	Marijana Bras, Croatia	Presenter
012	The investigating of the effectiveness of biofeedback (galvanic skin response) on war veterans with PTSD
	Mehdi Sahragard Toghchi, Iran	Presenter
013	The investigating of the effectiveness of eye movement desensitization and reprocessing on war veterans with PTSD
	Mehdi Sahragard Toghchi, Iran	Presenter
014	Posttraumatic stress disorder (PTSD): The impact of changes in diagnostic criteria
	Michael Van Ameringen, Canada	Presenter
015	Childhood maltreatment accociated with greater symptom secerity and poorer quality of life and function in social anxiety disorder
	Michael Van Ameringen, Canada	Presenter
016	The behavioral and neurochemical Ladasten effects depend on emotional stress reaction responses
	Mikhail Voronin, Russia	Presenter
017	Plasma serotonin level of Vietnam War veterans with posttraumatic stress disorder after long-term drug treatment
	Moon-Y. Chung, Korea, Republic of	Presenter
018	Dynamics of biological age dimensions after exposure to extreme situations
	Svetlana Tsaregorodtseva, Russia	Presenter
019	Caffeine challenge and breath-holding duration in patients with panic disorder
	Vasilios Masdrakis, Greece	Presenter
020	Efficacy of sertindole and combination of flufenazine and one SSRI (fluoxetine or fluvoxamine) in treatment of PTSD patients with psychotic symptoms
	Vladimir Grosic, Croatia	Presenter
021	Preliminary data on the French version of the Hypomania Checklist (HCL-32)
	E. Hantouche, France	Presenter

No.	P-24 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Neurodegenerative Disorders
Session title:	Neurodegenerative Disorders II
	Serge Gauthier, Canada	Chair

001	Peculiarities and treatment of delirium in geriatrics patients with traumatic injuries
	Liubov Romasenko, Russia	Presenter
002	Effects of glycine on learning, memory ability and hippocampal gene expression of APP, PS1, BACE in rats with Alzheimer disease
	Bai Han, China, People's Republic of	Presenter
003	Study on Chinese herb Danshen-Dahuang on learning, memory ability and hippocampal Tau and Aß in rats with Alzheimer disease
	Bai Han, China, People's Republic of	Presenter
004	The study on the level of intestinal endotoxemia in Alzheimer’s disease rats
	Bai Han, China, People's Republic of	Presenter
005	Amisulpride in the treatment of very late onset schizophrenia
	Constantin Psarros, Greece	Presenter
007	Behavior and attention disorders at the children with intellectual disabilities
	Dragana Macesic-Petrovic, Serbia and Montenegro	Presenter
008	Age-dependent induction of neurofibrillary tangles in transgenic mice overexpressing a non-mutant human tau isoform
	Etsuko Oshima, Japan	Presenter
009	Exploratory efficacy in cross-maze test depends on neurochemical profile of brain
	Georgy Kovalev, Russia	Presenter
010	Enhancing resilience to stress and quality of life in depressed family dementia caregivers: A randomized placebo-controlled trial of escitalopram
	Helen Lavretsky, USA	Presenter
012	Comparison of frontotemporal dementia and healthy volunteers using quantative EEG
	Keiichiro Nishida, Japan	Presenter
013	The role of oxidative stress in Mild Cognitive Impairment and Alzheimer disease
	Manuela Padurariu, Romania	Presenter
014	Creatine deficiency syndrome: Study of a cohort of 530 patients in the CHU of Rouen
	Marc Chévrier, France	Presenter
015	Persistence of abnormal cortisol levels in elderly persons after recovery from major depression
	Marie Laure Ancelin, France	Presenter
016	Tactile perception in children with intellectual disabilities
	Mirjana Japundza-Milisavljevic, Serbia and Montenegro	Presenter
017	Depression in Parkinson’s disease: Serotonin mechanisms, response to SSRI antidepressants
	Natalya Demchuk, Russia	Presenter
018	Copper binding effect on amyloid peptide aggregation in Alzheimer's disease
	Nuria Durany, Spain	Presenter
019	Memory performance in patients with obstructive sleep apnea before and after positive airway pressure
	Perbal Séverine, France	Presenter
020	Psychosis in Parkinson’s disease patients: The relevance of dopaminergic drugs and of their mode of application
	Ronald Saurugg, Austria	Presenter
021	Switching strategy involving Galantamine in the treatment of patients with mild to moderate Alzheimers disease
	Tae-Young Hwang, Korea, Republic of	Presenter

No.	P-25 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders V
	Norio Ozaki, Japan	Chair

001	Reaction time to sound and light in schizophrenic patients and normal people
	Alireza Homayouni, Iran	Presenter
002	Reasons for adherence to antipsychotic treatment: The patient's perspective
	Antonio Ciudad, USA	Presenter
003	Plasma homocysteine, folate and B12 levels in Tunisian patients with schizophrenia
	Anwar Mechri, Tunisia	Presenter
004	Niacin skin flush response in schizophrenia linked to soluble interleukin 2 receptor serum levels
	Berko Milleit, Germany	Presenter
005	TH-1/TH - 2 cytokine imbalance more pronounced in neuroleptic - naïve first episode schizophrenia
	Berko Milleit, Germany	Presenter
006	Expressiveness and recognition of self-generated facial emotions are impaired in schizophrenia
	Caroline Demily, France	Presenter
007	Addition of aripiprazole improves antipsychotic-induced hyperprolactinemia and reverses amenorrhea: Two cases
	Paraskevi Kotorki, Greece	Presenter
008	Fugue and aphonia as first and foremost presentations of a case of psychosis
	Ioanna Fotara, Greece	Presenter
009	Self-other discrimination in schizophrenic patients
	Christine Heinisch, Germany	Presenter
010	Suicide attempts in schizophrenic patients
	Christos Istikoglou, Greece	Presenter
011	A cognitive investigation of delusions: Are positive schizotypal symptoms associated with cognitive dysfunction and biases?
	Clare Cameron, Australia	Presenter
012	Serum proBDNF / BDNF ratio in patients with schizophrenia
	Davide Carlino, Italy	Presenter
013	The efficacy of atypical and classical antipsychotic agents in the acute treatment of schizoaffective disorders
	Djendji Siladji Mladenovic, Serbia and Montenegro	Presenter
014	Neurobiological vulnerabitlity determinded by vascular factor in schizophrenia
	Dragos Marinescu, Romania	Presenter
015	Neuroprotecion and cardioprotection for the antipsychotics with long - term action (animal model study)
	Laurentiu Mogoanta, Romania	Presenter
016	Negative symptoms in schizophrenia
	Edith Serfaty, Argentina	Presenter
017	Assessment of risk factors in tardive dyskinesia
	Melek Vardar, Turkey	Presenter
018	Minor physical anomalies in schizophrenic and schizoaffective patients and non - psychiatric controls: Assessment of group - and sex - specific differences
	Gordana Rubesa, Croatia	Presenter
019	Toluene exposure during adolescence produces long-lasting schizophrenia - like behaviors in mice
	Hwei-Hsien Chen, Taiwan	Presenter
020	Effects of Risperdal Consta on psychosocial functioning in schizophrenia
	Izabela Filov, Macedonia, The former Yugoslav	Presenter

No.	P-26 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Brain Function
Session title:	Brain Function III
	Matthaeus Willeit, Austria	Chair

001	Emotional processing within the Subthalamic nucleus in human
	Marie-Laure Welter, France	Presenter
002	A novelty / familiarity signal in the human dorsal thalamus
	Björn Schott, Germany	Presenter
003	No differences in the prevalence of cavum septum pellucidum and adhesio interthalamica between first-episode psychotic patients and healthy controls: A population-based study
	Clarissa Trzesniak, Brazil	Presenter
004	Reduced left hippocampal N-Acetylaspartate (NAA) in panic disorder patients detected by (1)H magnetic resonance spectroscopy imaging
	Clarissa Trzesniak, Brazil	Presenter
007	Basal hypothalamic pituitary adrenal axis activity and hippocampal volumes: The SMART-MR study
	Lotte Gerritsen, Netherlands	Presenter
008	Early and late life events and salivary cortisol in older persons
	Lotte Gerritsen, Netherlands	Presenter
009	Spatial memory following neurotoxin lesion of the basal cholinergic system
	Manana Dashniani, Georgia	Presenter
010	Correlation and predictor characteristics of the interhemispheric balance and Romberg's coefficient after electroconvulsive therapy
	Manol Gospodinov, Bulgaria	Presenter
011	Potentiation of Gamma Oscillatory Activity through Repetitive Transcranial Magnetic Stimulation (rTMS) of the Dorsolateral Prefrontal Cortex in Healthy Subjects
	Mera S. Barr, Canada	Presenter
012	Manic episode associated with temporal lobe epilepsy and sclerosis of amygdala and left hippocampal: A case report
	Mohamedi Darghal, Morocco	Presenter
013	Ultrastructural alterations of astrocytes in the hippocampus in schizophrenia
	Natalia Kolomeets, Russia	Presenter
014	The role of electroencephalography in diagnostic process in psychiatry - case report
	Nensi Manuseva, Macedonia, The former Yugoslav	Presenter
015	Metabolic syndrome in brain injury patients in a rehabilitation hospital
	Pardeep Singh Kundi, United Kingdom	Presenter
016	Peripheral nerve injury alters dopamine receptor numbers in the nucleus accumbens in a subpopulation of rats, which display sensory and affective disabilities
	Paul Austin, Australia	Presenter
017	Integrative function of single neurons in the human subthalamic nucleus during checking behavior
	Pierre Burbaud, France	Presenter
018	Age-related increase of the number of oligodendrocytes is dysregulated in the prefrontal cortex in schizophrenia and mood disorders
	Victor Vostrikov, Russia	Presenter
019	Involvement of the brain in the regulation of liver cytochrome P450 expression
	Wladyslawa Daniel, Poland	Presenter
021	Effects of pre-sleep negative mood induction on subsequent sleep
	Marie Vandekerckhove, Belgium	Presenter

No.	P-27 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Genetics
Session title:	Genetics II
	Dan Rujescu, Germany	Chair

002	Assessing the Pharmacokinetics of Venlafaxine Extended Release 75 mg and Desvenlafaxine 50 mg in CYP2D6 Extensive and Poor Metabolizers
	Karen Tourian, France	Presenter
003	Association between Tryptophan hydroxylase-2 gene variations and the personality traits of novelty seeking and harm avoidance
	Chan-Hyung Kim, Korea, Republic of	Presenter
004	Possible association between Serotonin transporter Gene Polymorphism (5-HTTLPR) and SSRI (Sertraline) treatment response in post traumatic stress disorder
	Dhuha Mushtaq, India	Presenter
005	Polymorphisms of 5-HTR2A and 5-HTT genes in patients with neurotic, stress-related and somatoform disorders
	Elena Gutkevich, Russia	Presenter
006	Familial depression associated with two novel T8310G and T8311A mtDNA mutations
	Gabriella Inczedy-Farkas, Hungary	Presenter
007	Stress associated changes in the nitric oxide signaling cascade in a genetic animal model of depression
	Gregers Wegener, Denmark	Presenter
008	Association of polumorphisms of TPH2 gene with risk for bipolar disorder and suicidal behavior
	Humberto Correa, Brazil	Presenter
009	Association study between Tryptophan Hydroxylase type II gene and late onset depression
	Humberto Correa, Brazil	Presenter
010	Post partum depression: Association study with Val66Met polymorphism of BDNF gene
	Humberto Correa, Brazil	Presenter
011	Association analysis of 44 candidate genes with depressive and anxiety symptoms in post-partum women
	Javier Costas, Spain	Presenter
012	Stimulated gene expression profiles as a blood marker in drug-naive major depressive disorder patients
	Jeroen van Zanten, Netherlands	Presenter
013	Personality traits and genetic polymorphisms of healthy Ugandans and Japanese
	Jun Miura, Japan	Presenter
014	Diras2 is associated with adult attention-deficit / hyperactivity disorder
	Lena Weißflog, Germany	Presenter
015	Serotonin transporter and BDNF genes variants in borderline personality disorder
	Hernan Silva Ibarra, Chile	Presenter
016	Effect of the alpha 2A-adrenergic receptor gene polymorphisms on antidepressant response in major depressive disorder
	Masataka Wakeno, Japan	Presenter
017	De novo Alu-mediated mutations of endoplasmic reticulum stress-related genes in schizophrenia
	Mikako Ueno, Japan	Presenter
018	Family association study of candidate genes in schizophrenia
	Pawel Kapelski, Poland	Presenter
019	Determination of emotional endophenotypes: A validation of the Affective Neuroscience Personality Scale
	Sylvie Berthoz, France	Presenter
020	S100B as a marker of inflammation in chidren and adolescents with first episode psychosis
	Tatiana Falcone, USA	Presenter
021	Functional polymorphism of matrix metalloproteinase-9 gene in major psychoses
	Janusz Rybakowski, Poland	Presenter

No.	P-28 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychopharmacology
Session title:	Psychopharmacology/ Antipsychotics
	James L. Kennedy, Canada	Chair

001	Trend in antipsychotic polypharmacy: A review of emergency prescriptions in a psychiatric hospital in Romania
	Madalina Ionelia Vrabie, Romania	Presenter
002	High dose of escitalopram in the treatment of obsessive compulsive disorder in a teaching hospital in Malaysia
	Amer Siddiq Amer Nordin, Malaysia	Presenter
003	A method to reduce polypharmacy and maximize effectiveness in chronically mentally Ill patients
	Andre Tapp, USA	Presenter
004	Antidepressant effect of antipsychotics in Schizophrenia: Comparison of typical and atypical antipsychotic drugs
	Antonio Sá, Brazil	Presenter
005	Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol
	Antonio Sá, Brazil	Presenter
006	Translation from the dopamine-glutamate interaction to antipsychotic pharmacotherapy: Role of Homer
	Carmine Tomasetti, Italy	Presenter
007	Acute efficacy of Olanzapine long-acting injection, oral Olanzapine, and haloperidol in patients with schizophrenia: A cross-study comparison
	Chris Bushe, USA	Presenter
008	Weight gain and changes in metabolic parameters during treatment with antipsychotics and Metformin : A systematic review of clinical studies
	Chris Bushe, USA	Presenter
009	Striatal and Extrastriatal D2/3-receptor binding properties of Quetiapine
	Hildegard Janouschek, Germany	Presenter
010	Glutamate and adenosine receptors mediate transcriptional activity induced by dopamine D2 antagonists in the striatum
	Jerome Maheux, Canada	Presenter
011	Efficacy and tolerability among patients with recent onset schizophrenia treated with long - acting injectable risperidone - PROPEL study
	Jonathan Rabinowitz, Israel	Presenter
012	Premorbid functioning and treatment response among patients with recent onset schizophrenia: Prospective study with risperidone long-acting injectable - PROPEL study
	Jonathan Rabinowitz, Israel	Presenter
013	Psychosis and Hiperprolactinemia in male patient: Contributions to pathophysiology and treatment
	Jose Lisandro Pabon Davila, Venezuela	Presenter
014	Repeated occurrence of clozapine-induced myocarditis in a patient with schizoaffective disorder and comorbid Parkinson´s disease
	Ladislav Hosak, Czech Republic	Presenter
015	Asenapine: An overview of phase I pharmacokinetic studies
	Pierre Peeters, Netherlands	Presenter
016	Amelioration of MK-801-induced cognitive impairment by lurasidone in mouse contextual fear conditioning test
	Satoko Baba, Japan	Presenter
017	Quetiapine Alleviates the Cuprizone-induced Demyelination and promotes the Remyelination Following Withdrawal of Cuprizone
	Xin-Min Li, Canada	Presenter
018	Risperidone long-acting injectable and Olanzapine pamoate: Review of short- and long-term safety data
	Guadalupe Martinez, Spain	Presenter
019	Descriptive analyses of the aripiprazole arm in the Risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)
	Guadalupe Martinez, Spain	Presenter
020	Functional improvement in Schizophrenia and schizoaffective disorder: Results from the Risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)
	Guadalupe Martinez, Spain	Presenter

No.	P-29 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychopharmacology
Session title:	Psychopharmacology/ Antidepressants
	Pierandrea Muglia, United Kingdom	Chair

002	Frequency of treatment-emergent sexual dysfunction in outpatients with major depressive disorder treated with either duloxetine or a selective serotonin reuptake inhibitor antidepressant: 8-week observational data
	Hector Duenas, Mexico	Presenter
003	Anxiolytic - and antidepressant-like effects in multiple preclinical assays shown by Lu AA21004, a novel drug
	Bjarke Ebert, Denmark	Presenter
004	Lu AA21004, a novel drug for the treatment of mood disorders: In vitro profile
	Bjarke Ebert, Denmark	Presenter
005	Lu AA21004, a novel potential treatment for mood disorders: In vivo effects
	Bjarke Ebert, Denmark	Presenter
007	Imipramine reverses oxidative damage in rat hippocampus in the absence and presence of chronic inhaled ozone: Support for a role of oxidative stress in depression
	Christiaan Brink, South Africa	Presenter
008	Duloxetine versus escitalopram in the treatment of major depressive disorder and generalized anxiety disorder dual diagnosis
	Daniel Vasile, Romania	Presenter
009	Milnacipran efficacy in major depressive disorder and alcohol dependence dual diagnosis
	Daniel Vasile, Romania	Presenter
010	Tianeptine efficacy in the treatment of multiple sclerosis associated anxiety disorder
	Daniel Vasile, Romania	Presenter
011	Comparison of Sertralines efficacy and tolerance with those of Clomipramine during the treatment of patients with obssessive compulsive disorder
	Elga Spaho, Albania	Presenter
012	A unifying theory of antidepressant action
	Francis Lavergne, France	Presenter
013	Cyclooxygenase (COX)-2 inhibition in depression: Evidence from animal studies
	Inge Sillaber, Germany	Presenter
014	Sexually dimorphic effects of antidepressant imipramine on glucocorticoid receptor hormone binding properties and association with heat shock proteins in the rat liver and kidney
	Ivana Elakovic, Serbia and Montenegro	Presenter
015	Preperential prevention of apoptosis by citalopram in mouse cortical cell cultures
	Jai-Sung Noh, Korea, Republic of	Presenter
017	Effect of monoaminergic antidepressant drugs on the hippocampal neurogenesis in a model of depression
	Parichehr Hassanzadeh, Iran	Presenter
019	Paroxetine specificity profile in major depression
	Sara Gibiino, Italy	Presenter
020	The role of fluoxetine in treatment of obsessive-compulsive disorder and co-substance abuse-a case report
	Mira Krivokuca, Serbia and Montenegro	Presenter
021	The most severe somatic disorders treated with excitalopram - more than just survival
	Sanja Kaludjerovic, Serbia and Montenegro	Presenter
022	The most severe somatic disorders treated with excitalopram
	Sanja Kaludjerovic, Serbia and Montenegro	Presenter
001	Tandospirone augmentation therapy is useful in depressed patients with inadequate response to SSRIs or SNRIs (Subsequent report)
	Akitsugu Sumiyoshi, Japan	Presenter

No.	P-30 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Other
Session title:	Other/ Suicide/ PTSD
	Philippe Courtet, France	Chair

001	What do we really know about mindfulness meditations?
	Alberto Chiesa, Italy	Presenter
002	Mindfulness based stress reduction for stress management in healthy people: A review and meta-analysis
	Alberto Chiesa, Italy	Presenter
003	Executive Functions with affective involvement in patients with suicide attempt
	Eduardo Salvador Martínez Velázquez, Mexico	Presenter
004	Suicidal behavior associated to obsessive compulsive disorder in a mental health institution
	Freddy Vasquez, Peru	Presenter
005	Suicidality and Phagophobia
	Freddy Vasquez, Peru	Presenter
006	Effectiveness of a practice guideline for ambulatory treatment of Colombian patients with suicide risk
	German Eduardo Rueda-Jaimes, Colombia	Presenter
007	Predictive validity of the suicide behavior questionnaire - revised in Colombian psychiatry patients with suicide risk
	German Eduardo Rueda-Jaimes, Colombia	Presenter
008	Migraine comorbidity in Bipolar Disorder patients
	German Eduardo Rueda-Jaimes, Colombia	Presenter
009	Occupational stress among administrative personnel in mental health hospitals
	Gyonyul Hayredin, Bulgaria	Presenter
010	Emotionally-strong-willed sphere of the person with information neurosis
	Helena Simonenko, Ukraine	Presenter
011	Psychological and neuroendocrine responses in male residents after an overnight hospital call
	Jasdeep Miglani, USA	Presenter
012	Treatment emergent sexual dysfunction related to antidepressants: A meta-analysis
	Alberto Chiesa, Italy	Presenter
013	Suicidal attempt cases admitted within a year in a general hospital
	Nikolaos Kouroumalos, Greece	Presenter
014	Environmental enrichment rescues the behavioural phenotype of BDNF heterozygous mice
	Peter Gass, Germany	Presenter
015	Is allergen exposure a contributing factor to suicidality?
	Ping Qin, Denmark	Presenter
016	Suicidal ideation and hopelessness - is this the psychological marker?
	Saroja Krishnaswamy, Malaysia	Presenter
017	Risk factors of suicidality in patients with social phobia
	Kang-Seob Oh, Korea, Republic of	Presenter
018	Social factors in the prevention of suicidal attempts in Saudi Arabia
	Yasein Elgaddal, Saudi Arabia	Presenter
019	Laboratorial findings in 300 fibromyalgia patients. A review
	Gloria Pizzuto, Argentina	Presenter
020	Malignant evolution of fibromyalgia. About one case
	Gloria Pizzuto, Argentina	Presenter
021	Fibromyalgia and children abuse stress in circa 300 cases
	Gloria Pizzuto, Argentina	Presenter
022	Eponyms from the Nazi era of relevance to biological and neuro-psychiatry: Remember some, change some
	Rael Strous, Israel	Presenter

No.	P-31 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Other
Session title:	Other/ Mental Health
	Anu Kant Mital, India	Chair

001	Epidemiology
	Adebowale Yusuf Adedoja, Nigeria	Presenter
002	Evolution of psichiatric emergencies
	Ana Sáenz Ballobar, Spain	Presenter
003	Psychiatric consultation in a general hospital - Biological and clinical data: Prospective study
	Anna Falces, Spain	Presenter
004	Mental Health Recovery: An illusive concept
	Christos Tsopelas, Greece	Presenter
005	The non government organization in the process of psychiatric attention, the case of a hospital in Mexico City
	Claudio Garcia, Mexico	Presenter
006	Translating biological parameters into clinically-useful diagnostic tests
	Cynthia Arfken, USA	Presenter
007	Mental healt primary attention model experence
	Daniel Lucatero, Mexico	Presenter
008	The coercive measures in psychiatric emergency service. Differences on different diagnoses
	Jose Maria Gines Miranda, Spain	Presenter
009	Therapeutic adherence clinic: An alternative to make psychiatric treatment efficient
	Horacio Reza, Mexico	Presenter
010	Psychiatry illness and medical comorbidity, do they really prolong the length of stay?
	Jorge Cuevas, Spain	Presenter
011	Hospital re-admission of patients with mental and behavioral disorders in Mexico
	Jose Luis Garcia-Aguirre, Mexico	Presenter
012	Rapid tranquillisation practice in Zambia: A survey
	Mahesh Jayaram, United Kingdom	Presenter
013	Common mental disorders among immigrants in Santigo de Chile
	Maria Graciela Rojas, Chile	Presenter
014	Immigration in Chile: Mental health problems. A comparison between immigrants and local population
	Maria Graciela Rojas, Chile	Presenter
015	Physical illness and common mental disorders in primary care
	Miquel Roca Bennásar, Spain	Presenter
016	Contemporary ethics and informed consent in psychiatric research: seeking the truth or attempting to override it?
	Platon Christopoulos, Greece	Presenter
017	Emergency psychiatry
	Rita Delattibodier, Honduras	Presenter
018	Strategies for the renewal of significance of psychiatric attention in Mexico
	Sandra Esquivel, Mexico	Presenter
019	Attitudes to psychiatric services and compliance in migrant families
	Türkan Akkaya-Kalayci, Austria	Presenter
020	Essential fatty acids in inflammatory and immune response in psychiatric diseases
	Iris Ilona Lieber, Argentina	Presenter
021	Influence of insulin and altered carbohydrate metabolism in psychiatric disorders
	Iris Ilona Lieber, Argentina	Presenter

No.	FC-21 - Free Communications
Time:	14.00-15.30
Room:	Room 242A
Topic:	Other
Session title:	Other III
	Peter Falkai, Germany	Chair
	N N	Co-Chair

001	Neural substrates of Anorexia Nervosa: A review of structural and functional neuroimaging studies
	Valentina Meuti, Italy	Speaker
002	Influence of parental rearing attitudes on gene expressions of glucocorticoid signaling in peripheral blood cells of healthy young adults
	Tomoko Kawai, Japan	Speaker
003	Iatrogenic Hypothermia - a case report
	Rosa Rodrigues, Portugal	Speaker
004	Shared neurobiological markers in autism and fragile x syndrome with autistic features, however….
	Nagwa Meguid, Egypt	Speaker
005	Hypothalamic-Pituitary-Adrenal (HPA) hypoactivity in circa 200 Fibromyalgia or Chronic fatigue (CFS) patients. Cortisol rhythm, Dexamethasone Supression Test (DST) and Free urinary cortisol (CLU.)
	Andrea Lopez Mato, Argentina	Speaker
006	Long term outcome in prepubertal anorexia nervosa: A retrospective study of young adult subjects
	Laura Bignami, France	Speaker

No.	FC-22 - Free Communications
Time:	14.00-15.30
Room:	Room 242B
Topic:	Brain Function
Session title:	Brain Function II
	Klaus Ebmeier, United Kingdom	Chair
	Georg Juckel, Germany	Co-Chair

001	Mental fatigue and impaired information processing after brain injury
	Lars Rönnbäck, Sweden	Speaker
002	A meta-analysis comparing the placebo response of a non-pharmacological vs. a pharmacological intervention in major depressive disorder
	Andre Brunoni, Brazil	Speaker
003	Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor
	Tatiana Melnikova, USA	Speaker
004	Increased vulnerability of the mesencephalic dopaminergic systems of the human neonate to perinatal hypoxia: Implications in psychiatry
	Maria Panayotacopoulou, Greece	Speaker
005	Autonomic nervous system and its association with brain function in major depressive disorder
	Tye Dawood, Australia	Speaker
006	Striatum abnormalities in schizophrenia patients` families
	Vera Orlova, Russia	Speaker

No.	SA-04 - Satellite Symposium
Time:	14.00-15.30
Room:	Blue Amphitheatre
Topic:
Session title:	Shedding light on the signal of darkness: Melatonin in sleep and CNS disorders supported by an unrestricted educational grant from Lundbeck A/S
	Anna Wirz-Justice, Switzerland	Chair

001	Melatonin as a timekeeper
	Anna Wirz-Justice, Switzerland	Speaker
002	Melatonin rhythm in CNS disorders
	Dieter Kunz, Germany	Speaker
003	Melatonin, sleep and the elderly
	Raymond Cluydts, Belgium	Speaker

No.	SA-05 - Satellite Symposium
Time:	14.00-15.30
Room:	Salle Maillot
Topic:
Session title:	Long term treatment in schizophrenia - strategies to help maximise individual patient outcomes sponsored by Eli Lilly and Company
	Frederic Rouillon, France	Chair

001	A decade of experience with oral atypical antipsychotics
	John Davis, USA	Speaker
002	Current barriers to successful patient outcomes: Is change possible?
	Joseph Peuskens, Belgium	Speaker
003	Can novel atypical depots make a difference?
	Luis San, Spain	Speaker

No.	TG-06 - WFSBP Treatment Guidelines
Time:	16.00-17.30
Room:	Room 242A
Topic:	Psychotic Disorders
Session title:	Schizophrenia
	Birte Glenthoj, Denmark	Chair

	Carlo Altamura, Italy	Presenter
	Peter Falkai, Germany	Presenter

No.	D-06 - Debate
Time:	16.00-17.30
Room:	Room 351
Topic:	Other
Session title:	Clinical relavance of neurogenesis and/or intracellular mechanisms
	Toshikazu Saito, Japan	Chair

	Husseini Manji, USA	Proponent
	Michel Hamon, France	Opponent

No.	W-08 - Workshop
Time:	16.00-17.30
Room:	Room 242B
Topic:	Childhood Adolescent Disorder
Session title:	Mastering the challenges in conducting multinational child and adolescent psychopharmacology trials
	Adelaide Robb, USA	Chair

001	Ensuring data quality and consistency in multinational clinical trials
	Margaretta Nyilas, USA	Speaker
002	Ethical, clinical and practical considerations in designing clinical trials in paediatric psychopharmacology
	Philippe Auby, France	Speaker

No.	S-54 - Symposium
Time:	16.00-17.30
Room:	Blue Amphitheatre
Topic:	Neurodegenerative Disorders
Track:	1 Basic
Session title:	Aß Immunotherapy of Alzheimer's disease
	Siegfried Kasper, Austria	Chair
	Serge Gauthier, Canada	Co-Chair

001	Selection of efficacy outcomes in disease-modifying trials that are meaningful to clinicians, patients and payers
	Serge Gauthier, Canada	Speaker
002	Biomarkers in Alzheimer's disease: Use for clinical trials
	Anton Alvarez, Spain	Speaker
003	AD vaccines: The new generation - successes and challenges on its way into clinical practice
	Achim Schneeberger, Austria	Speaker
004	AFFITOPES of Aß as active vaccines in the treatment of AD: results of a phase I study with AFFITOPE AD02
	Alexandra Kutzelnigg, Austria	Speaker

No.	S-55 - Symposium
Time:	16.00-17.30
Room:	Salle Maillot
Topic:	Psychotic Disorders
Track:	1 Basic
Session title:	EEG and MEG response to mismatch stimuli as an index of schizophrenia neurobiology and genetics
	Robert McCarley, USA	Chair
	Kiyoto Kasai, Japan	Co-Chair

001	Mismatch negativity from the prodrome to chronicity: Relationships with functional status, generator sources and grey matter loss
	Pat Michie, Australia	Speaker
002	Deficits in primary auditory cortex circuits in subjects with schizophrenia: Matching up with mismatch negativity
	Robert Sweet, USA	Speaker
003	MEG mismatch abnormalities to speech sounds in schizophrenia: Heritability and relationship to genetics
	Tsuyoshi Araki, Japan	Speaker
004	Mismatch negativity is associated with genetic, clinical, cognitive, and functional abnormalities of schizophrenia patients
	Gregory Light, USA	Speaker

No.	S-56 - Symposium
Time:	16.00-17.30
Room:	Room 352AB
Topic:	Psychopharmacology
Track:	3 Interface
Session title:	Recent developments in affective disorders during pregnancy and lactation
	Angelika Wieck, United Kingdom	Chair
	Carmine Pariante, United Kingdom	Co-Chair

001	Recent developments in antenatal depression
	Carmine Pariante, United Kingdom	Speaker
002	New data on the reproductive safety of antidepressant drugs
	Margareta Reis, Sweden	Speaker
003	New insights into bipolar disorder in childbearing women
	Ian Jones, United Kingdom	Speaker
004	The safety of mood stabilizing medication in pregnancy and lactation
	Salvatore Gentile, Italy	Speaker

No.	S-57 - Symposium
Time:	16.00-17.30
Room:	Room 252B
Topic:	Affective Disorders (Unipolar)
Track:	2 Clinical
Session title:	Depression, vitamin D and light
	Witte Hoogendijk, Netherlands	Chair
	Consuelo Hopkins Wilkins, USA	Co-Chair

001	Vitamin D, light and parathyroid hormone in depression
	Witte Hoogendijk, Netherlands	Speaker
002	Positive effect of bright light in non-seasonal depression
	Ritsaert Lieverse, Netherlands	Speaker
003	Developmental vitamin D deficiency alters adult behaviour
	Thomas Burne, Australia	Speaker
004	Vitamin D deficiency is associated with low mood and worse cognitive performance
	Consuelo Hopkins Wilkins, USA	Speaker

No.	S-58 - Symposium
Time:	16.00-17.30
Room:	Room 241
Topic:	Neuroimaging
Track:	1 Basic
Session title:	Are there really progressive brain abnormalities in association with schizophrenia? Current longitudinal magnetic resonance imaging studies from at ri
	Geraldo F. Busatto, Brazil	Chair
	René Kahn, Netherlands	Co-Chair

001	Progressive brain changes across the transition to psychosis: Where to from here?
	Stephen J. Wood, Australia	Speaker
002	Brain changes 6 years after the first episode of a psychosis
	Paola Dazzan, United Kingdom	Speaker
003	Brain changes in schizophrenia across the age range
	René Kahn, Netherlands	Speaker
004	Longitudinal MRI investigation of brazilians with first-onset psychosis over 4 years
	Maristela Schaufelberger, Brazil	Speaker

No.	S-59 - Symposium
Time:	16.00-17.30
Room:	Room 251
Topic:	Brain Function
Track:	3 Interface
Session title:	New strategies and tools in the field of transcranial magnetic stimulation (TMS)
	Yechiel Levkovitz, Israel	Chair
	Frank Padberg, Germany	Co-Chair

001	Deep transcranial magnetic stimulation in major depression: Feasibility and safety study
	Yechiel Levkovitz, Israel	Speaker
002	New protocols of non-invasive brain stimulation: Enhancing the after-effect
	Frank Padberg, Germany	Speaker
003	Gamma synchrony, GABAB and rTMS cognitive enhancing strategies in schizophrenia
	Z. Jeff Daskalakis, Canada	Speaker
004	Physiological optimization of TMS pulse shape and parameters for therapeutic applications: Controllable pulse shape TMS (cTMS) and magnetic seizure therapy (MST)
	Sarah H. Lisanby, USA	Speaker

« previous day

Tuesday, 30. June 2009

next day »